Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Okomera logo — Automated 3D organoid screening technology

Okomera

Automated 3D organoid screening technology

Founded 2020 France France 30 employees Grant Total: $11.70M Biotechnology, Health and Wellness +1

General Information

Company Name Okomera
Founded Year 2020
Location France France +2
Employees 30
Industries Biotechnology, Health and Wellness, Life Sciences
Funding Stage Grant
Social

Get notified when Okomera moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Okomera

Okomera is a biotechnology startup based in France that specializes in automated 3D organoid screening technology. Since its founding in 2020, the company has focused on accelerating drug discovery through the integration of standard assays on chip, such as CRISPR, T-cell, and cytotoxicity, with the aim of advancing preclinical predictivity. The company recently secured a significant €1.50M grant investment from Bpifrance on 21 October 2024. This investment is a testament to the potential and promise of Okomera's innovative approach to revolutionizing the drug discovery process.

Taxonomy: Biotech, Drug Discovery, 3D Organoid Screening, Precision Medicine, Cancer Research, Automation Technology, Tumor Biopsy Research, Preclinical Predictivity, CRISPR Technology, T-cell Assays, Cytotoxicity Assays

Services & Products

Automated 3D organoid screening technology
AI analysis platform
Personalized medicine

Target Customers

Biotech companies Pharmaceutical companies Medical research institutions

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1
Investor
21 Oct 2024
Grant •••••• 1
Investor
20 Dec 2023
Seed Round •••••• 5
Investor Investor Investor
•••• •••• 		20 Dec 2023
Non Equity Assistance •••••• 1
Investor
01 Jun 2020

Okomera Alternatives & Competitors

Okomera vs
Cell Technology, Inc.
Cell Technology, Inc. United States

Biological Tools for Life Science Research

2 employees
Okomera vs
Guava Technologies
Guava Technologies

Empowering medical advancements through innovative biotechnology and medical devices tailored for ce...

Series Unknown
Biotechnology, Health Care
Compare Okomera vs Guava Technologies
Okomera vs
Reaction Biology
Reaction Biology United States

Contract research organization with commitment to quality data and quality support. Let's Discover T...

Acquired
146 employees
Biotechnology, Pharmaceutical
Compare Okomera vs Reaction Biology
Also compare with: Okomera vs Nordic Biomarker Nordic Biomarker

FAQ About Okomera

Automated 3D organoid screening technology
Okomera was founded in 2020.
Okomera is headquartered in France.
Okomera operates in the following industries: Biotechnology, Health and Wellness, Life Sciences.
Okomera has approximately 30 employees.
Okomera has completed 4 funding rounds, raising a total of $11.70M. The latest funding stage is Grant.
Okomera offers: Automated 3D organoid screening technology, AI analysis platform, Personalized medicine.
Top alternatives and competitors to Okomera include Cell Technology, Inc., Guava Technologies, Reaction Biology, ADMEcell, Nordic Biomarker. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Okomera and Cell Technology, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Okomera and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy